CAS: 23593-75-1; Clotrimazole

上下游产品

CAS号288-32-4 咪唑 | CAS号102-10-3 diphenyl phosphite | CAS号66774-02-5 (2-氯苯基)二苯基甲醇 | CAS号108-10-1 甲基异丁基甲酮 | CAS号42074-68-0 2-氯三苯基氯甲烷 | CAS号66774-02-5 (2-氯苯基)二苯基甲醇

(2-氯苯基)二苯基甲醇置于三乙胺,N,N-二甲基甲酰胺体系中,用 二氯甲烷,乙腈 用作溶剂,化学反应 96.33H,反应生成克霉唑
参考文献:合成的 1-三苯甲基取代的 1H-咪唑的合成,评估,计算机 Admet 筛选,Hyde 评分和分子对接研究
标题:合成的 1-三苯甲基取代的 1H-咪唑的合成,评估,计算机 Admet 筛选,Hyde 评分和分子对接研究
摘要:三步合成方法使咪唑系列在结构上与克霉唑相关.首先,利用格氏反应将二苯甲酮衍生物转化为相应的三苯甲醇.然后,三苯基甲醇与亚硫酰氯(Socl 2 )反应形成三苯基氯甲烷.最终通过取代反应以较高的收率获得了咪唑衍生物.所有化合物和克霉唑均使用光谱方法进行表征,包括 Ftir,1 H NMR,13 C NMR,19 F NMR 和 Ms 光谱.使用琼脂扩散测试作为技术,测试了所得化合物针对白色念珠菌和细菌(藤黄微球菌和大肠杆菌)的生物活性.合成的化学品的咪唑部分 (6B) 显示出显着的抗菌活性和针对藤黄微球菌的体外活性.还进行了分子对接实验,以确定所产生的化合物与抗念珠菌唑靶酶羊毛甾醇14-α-去甲基酶(cyp51)活性位点之间的相互作用模式.大多数合成化合物的生物利用度都非常出色,这从它们的药物相似性和计算机 Admet 特征可以看出.因此,合成的化学物质可以被认为是进一步研究的潜在治疗候选者.
Doi:10.1007/s13738-023-02887-7

专利信息

专利号:US-12383499-B2
优先权日:2018-01-01
标题:Scale up synthesis of silicasome nanocarriers
发明人：NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
权利人:UNIV CALIFORNIA
摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-5798236-A
优先权日:1992-09-30
标 题 :Synthesis of quinic acid from glucose
发明人：FROST JOHN W; DRATHS KAREN M; WARD TIMOTHY L
权利人:GENENCOR INT
摘要:There are described methods for the synthesis of quinoid organic compounds from a renewable energy source such as glucose. The method comprises enhancing the amount of glucose equivalents introduced into the pathway, blocking the common pathway so as to accumulate dehydroquinate and converting the dehydroquinate to quinic acid.

专利号:US-11311505-B2
优先权日:2017-02-24
标 题:Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
发明人：MARTIN ALAIN
权利人:MARTIN ALAIN; CELLULAR SCIENCES INC
摘要:Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.